<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01021813</url>
  </required_header>
  <id_info>
    <org_study_id>4305-009</org_study_id>
    <secondary_id>2009_696</secondary_id>
    <nct_id>NCT01021813</nct_id>
  </id_info>
  <brief_title>A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)</brief_title>
  <official_title>A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Long Term Safety Study of MK-4305 in Patients With Primary Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will establish the safety and tolerability of suvorexant (MK-4305) when
      administered for up to 14 months. Participants will be randomized to receive suvorexant or
      placebo for a 12-month double-blind (DB) Treatment Phase. Participants who complete the
      12-month DB Treatment Phase will enter a 2-month DB Randomized Discontinuation Phase. At the
      time of initial randomization, participants assigned to receive suvorexant during the initial
      12-month Treatment Phase will be simultaneously randomized, in a 1:1 ratio, to receive either
      suvorexant or placebo during the 2-month Randomized Discontinuation Phase. Participants
      randomized to receive placebo in the initial 12-month Treatment Phase will continue to
      receive placebo during the 2-month Randomized Discontinuation Phase.

      The first 3 nights of the Randomized Discontinuation Phase are referred to as the Run-Out
      Phase, and will assess rebound and withdrawal.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 10, 2009</start_date>
  <completion_date type="Actual">August 1, 2011</completion_date>
  <primary_completion_date type="Actual">May 17, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced Cataplexy Adverse Events (AEs) During the Double-Blind (DB) Treatment Phase</measure>
    <time_frame>From the first day of study treatment up to 12 months</time_frame>
    <description>Cataplexy is defined as a sudden loss of muscle tone while awake which prevents voluntary movement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced Sleep Paralysis AEs During the DB Treatment Phase</measure>
    <time_frame>From the first day of study treatment up to 12 months</time_frame>
    <description>Sleep paralysis was defined as the inability to perform voluntary muscle movements during sleep. Sleep paralysis adverse events included sleep-onset paralysis (paralysis as one is falling asleep).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced Complex Sleep-related Behaviors AEs During the DB Treatment Phase</measure>
    <time_frame>From the first day of study treatment up to 12 months</time_frame>
    <description>Complex sleep-related behaviors were reported as ECIs and were characterized by patients engaging in specific activities while asleep (e.g., eating, drinking, preparing meals, making phone calls, having sex, driving, and sleep walking).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced Falls AEs During the DB Treatment Phase</measure>
    <time_frame>From the first day of study treatment up to 12 months</time_frame>
    <description>Falls were adjudicated (to establish whether a fall event was due to cataplexy).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced Suicidal Ideation and/or Behavior AEs During the DB Treatment Phase</measure>
    <time_frame>From the first day of study treatment up to 12 months</time_frame>
    <description>Suicidal ideation included suicidal plans, suicidal tendency, death wishes, life weariness, and suicidal intention. Suicidal behaviors included suicide attempts, suicide gesture, and self-injurious behaviour. Suicidal ideation and/or behavior was reported as an AE and considered an ECI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced Hypnagogic/Hypnopompic Hallucinations AEs During the DB Treatment Phase</measure>
    <time_frame>From the first day of study treatment up to 12 months</time_frame>
    <description>Perceptual distortions associated with transitions between wakefulness and sleep were termed as hypnagogic (occurring during the onset of sleep) or hypnopompic (occurring during onset of wakefulness) hallucinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced Selected AEs Associated With Potential for Abuse During the DB Treatment Phase</measure>
    <time_frame>From the first day of study treatment up to 12 months</time_frame>
    <description>The pre-specified terms which were suggestive of abuse potential on this study included depersonalization (feeling of watching oneself act, while having no control over a situation), derealization (alteration in the perception or experience of the external world so that it seems unreal), dissociation (includes a wide array of experiences from mild detachment from immediate surroundings to more severe detachment from physical and emotional experience), euphoric mood (exaggerated feeling of physical and emotional well-being and optimism not consonant with apparent stimuli or events), mania (state of abnormally elevated or irritable mood, arousal, and/or energy levels), hallucination (perception in the absence of a stimulus which has qualities of real perception), and potential study medication misuse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Withdrawal Symptoms During the DB Run-Out Phase: Tyrer Withdrawal Symptom Questionnaire (WSQ)</measure>
    <time_frame>Evening of Month 12 visit and next 3 consecutive days (Night 1, 2, and 3 of Discontinuation Phase [otherwise known as the Run-out])</time_frame>
    <description>Withdrawal effects assessed using Tyrer WSQ, which evaluated the presence/absence and severity of withdrawal symptoms with 20 items (i.e. sensitivity to noise, light, smell, touch, feeling unreal, etc). The Tyrer WSQ was completed as part of the evening e-diary prior to dosing on the Month 12 visit and on the 3 consecutive evenings of the DB Run-out Phase (first 3 nights of DB Discontinuation Phase). Responses rated 0 (No), 1 (Yes-moderate), or 2 (Yes-severe); range from 0 (no withdrawal) to 40 (severe withdrawal).
A participant was defined to have a withdrawal symptom if an item during any of the 3 DB Run-out days had emerged for the first time, or had worsened compared to the measurement obtained at the end of the Treatment phase (Month 12). For single night analysis, a patient was defined to have withdrawal effects if the number of withdrawal symptoms (emergent or worsening) was ≥3. For across night analysis, withdrawal was defined as a total of ≥3 symptoms across the 3 nights.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Rebound As Defined By Decreased Subjective Total Sleep Time (sTST) During the DB Run-Out Phase</measure>
    <time_frame>Baseline (Month 1) and first 3 days of Randomized Discontinuation Phase (otherwise known as the Run-out, Month 13)</time_frame>
    <description>Rebound insomnia was defined as insomnia that occurred following discontinuation of a sedative substance taken to relieve primary insomnia, and was assessed based on subjective total sleep time (sTST) as recorded in the participant's morning e-diary. A strict categorical analysis method (Yes/No) was used in which a participant was considered to have potentially experienced rebound (Yes) if the Morning Diary participant-reported sTST value (in minutes) on any of the 3 nights of the Run-out Phase (first 3 nights of the Discontinuation Phase) occurring after one year of treatment (Month 13) was less than the last value at baseline one year earlier (Month 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Rebound As Defined By Increased Subjective Time to Sleep Onset (sTSO) During the DB Run-Out Phase</measure>
    <time_frame>Baseline (Month 1) and first 3 days of Randomized Discontinuation Phase (otherwise known as the Run-out, Month 13)</time_frame>
    <description>Rebound insomnia was defined as insomnia that occurred following discontinuation of a sedative substance taken to relieve primary insomnia, and was assessed based on subjective time to sleep onset (sTSO) as recorded in the participant's morning e-diary. A strict categorical analysis method (Yes/No) was used in which a participant was considered to have potentially experienced rebound (Yes) if the Morning Diary participant-reported sTSO value (in minutes) on any of the first 3 nights of the Run-out Phase occurring after one year of treatment (Month 13) was greater than the last value at baseline one year earlier (Month 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Least Squares (LS) Mean Change From Baseline in Mean Subjective Total Sleep Time (sTSTm) During First Month of Treatment Phase</measure>
    <time_frame>Baseline, Week 1, Week 2, Week 3, and Week 4</time_frame>
    <description>The sTSTm was defined as the average over time of daily e-diary values for a participant's report of the total amount of time spent asleep before waking for the day (measured in minutes). Weekly sTSTm values (Week 1, Week 2, etc.) were the average of the daily e-diary values for the week. A summary value of this measure for Month 1 was obtained by taking the average of weekly sTSTm values for Weeks 1 through 4; (Week 1 + Week 2 + Week 3 + Week 4) ÷ 4. LS Mean Change from Baseline in sTSTm was then calculated at Week 1, Week 2, Week 3, Week 4, and Month 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Least Squares (LS) Mean Change From Baseline in Mean Subjective Time To Sleep Onset (sTSOm) During First Month of Treatment Phase</measure>
    <time_frame>Baseline, Week 1, Week 2, Week 3, and Week 4</time_frame>
    <description>The sTSOm was defined as the average over time of daily e-diary values for a participant's report of the time he or she required to fall asleep (measured in minutes). Weekly sTSOm values (Week 1, Week 2, etc.) were the average of the daily e-diary values for the week. A summary value of this measure for Month 1 was obtained by taking the average of weekly sTSTm values for Weeks 1 through 4; (Week 1 + Week 2 + Week 3 + Week 4) ÷ 4. LS Mean Change from Baseline in sTSOm was then calculated at Week 1, Week 2, Week 3, Week 4, and Month 1.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants Who Reported Suicidal Ideation and/or Behavior On Study Based on Responses to the Columbia Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>From the first day of study treatment through study follow-up (up to 14 months)</time_frame>
    <description>Suicidal ideation and/or behavior that occurred on study was also assessed using the C-SSRS, a rater-administered questionnaire used to prospectively assess suicidal ideation and suicidal behavior. C-SSRS assessment was based upon a clinician's interpretation of the participant's responses to the C-SSRS questions, not by a numbered scale.
Suicidal ideation and/or behaviors identified on the C-SSRS may not have been considered an adverse event, based on the investigator's judgment.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">781</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Suvorexant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a 1-week single-blind placebo run-in, participants received suvorexant (40 mg for participants aged 18 to &lt;65 years; and 30 mg for participants aged ≥65 years) daily before bedtime for 12 months during the Treatment Phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After a 1-week single-blind placebo run-in, participants received dose-matched placebo to suvorexant (administered according to age) daily before bedtime for 12 months during the Treatment Phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suvorexant</intervention_name>
    <description>Oral tablet (30 mg and 10 mg), administered daily before bedtime</description>
    <arm_group_label>Suvorexant</arm_group_label>
    <other_name>MK-4305</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose-matched Placebo to Suvorexant</intervention_name>
    <description>Oral tablet, administered daily before bedtime</description>
    <arm_group_label>Suvorexant</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of primary insomnia

          -  Participant is able to read, understand, and complete questionnaires and diaries

          -  If female, participant and partner both agree to use acceptable contraception. If male
             partner does not use an effective form of contraception, female participant must use 2
             acceptable forms of contraception

          -  If ≥65 years of age, score of ≥25 on the Mini Mental State Examination (MMSE)

        Exclusion Criteria:

          -  If female, participant is pregnant

          -  Participant expects to donate eggs or sperm during the study

          -  Recent and/or active history of a confounding neurological disorder

          -  History of clinically unstable cardiovascular disorder within the last 6 months

          -  Lifetime history of bipolar disorder

          -  Psychiatric condition that requires treatment with a medication prohibited by the
             study, or any other psychiatric condition that would interfere with the participant's
             ability to participate in the study

          -  History of substance abuse/dependence

          -  History of cancer ≤5 years prior to study participation except for adequately treated
             basal cell or squamous cell skin cancer or in situ cervical cancer

          -  Evidence of suicidality (based on a score of 2 on the Quick Inventory of Depressive
             Symptomatology Self-Report 16-Item ([QIDS-SR16] suicide item #12)

          -  Participant has travelled across &gt;3 time zones or &gt;3 hour time difference in the last
             2 weeks

          -  History of permanent night shift work or rotating day/night shift work in the past 2
             weeks

          -  Body Mass Index (BMI) &gt;40 kg/m^2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2009</study_first_submitted>
  <study_first_submitted_qc>November 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2009</study_first_posted>
  <results_first_submitted>August 19, 2014</results_first_submitted>
  <results_first_submitted_qc>August 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 29, 2014</results_first_posted>
  <last_update_submitted>June 1, 2017</last_update_submitted>
  <last_update_submitted_qc>June 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suvorexant</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=4305-009&amp;kw=4305-009&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of the 781 participants randomized into the Treatment Phase, 522 were randomized to suvorexant and 259 were randomized to placebo. Two participants were randomized, but not treated (one from each treatment group); therefore, the total number of participants evaluated for safety was 779.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Suvorexant</title>
          <description>After a 1-week single-blind placebo run-in, participants received suvorexant (40 mg for participants aged 18 to &lt;65 years; and 30 mg for participants aged ≥65 years) daily before bedtime for 12 months during the double-blind (DB) Treatment Phase.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>After a 1-week single-blind placebo run-in, participants received dose-matched placebo to suvorexant (administered according to age) daily before bedtime for 12 months during the DB Treatment Phase.</description>
        </group>
        <group group_id="P3">
          <title>Suvorexant (DB Treatment)/Suvorexant (DB Discontinuation)</title>
          <description>Following treatment with suvorexant during the 12-Month DB Treatment Phase, participants received their same dose of suvorexant during a 2-month DB Randomized Discontinuation Phase.</description>
        </group>
        <group group_id="P4">
          <title>Suvorexant (DB Treatment)/Placebo (DB Discontinuation)</title>
          <description>Following treatment with suvorexant during the 12-Month DB Treatment Phase, participants received dose-matched placebo to suvorexant during a 2-month DB Randomized Discontinuation Phase.</description>
        </group>
        <group group_id="P5">
          <title>Placebo (DB Treatment)/Placebo (DB Discontinuation)</title>
          <description>Following treatment with dose-matched placebo to suvorexant during the 12-Month DB Treatment Phase, participants continued to receive dose-matched placebo to suvorexant during a 2-month DB Randomized Discontinuation Phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>DB Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="522"/>
                <participants group_id="P2" count="259"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="521"/>
                <participants group_id="P2" count="258"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="322"/>
                <participants group_id="P2" count="162"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="97"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>DB Randomized Discontinuation Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="156"/>
                <participants group_id="P4" count="166"/>
                <participants group_id="P5" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="152"/>
                <participants group_id="P4" count="161"/>
                <participants group_id="P5" count="157"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>781 participants were randomized on study (suvorexant=522, placebo=259). 2 participants were randomized but not treated, thus the total number of participants evaluated for baseline age and gender was 779 (suvorexant=521, placebo=258). 771 participants had data available for evaluation of baseline sleep parameters (suvorexant=517, placebo=254)</population>
      <group_list>
        <group group_id="B1">
          <title>Suvorexant</title>
          <description>After a 1-week single-blind placebo run-in, participants received suvorexant (40 mg for participants aged 18 to &lt;65 years; and 30 mg for participants aged ≥65 years) daily before bedtime for 12 months during the double-blind (DB) Treatment Phase.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>After a 1-week single-blind placebo run-in, participants received dose-matched placebo to suvorexant (administered according to age) daily before bedtime for 12 months during the DB Treatment Phase.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="521"/>
            <count group_id="B2" value="258"/>
            <count group_id="B3" value="779"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="14.5"/>
                    <measurement group_id="B2" value="62.0" spread="14.6"/>
                    <measurement group_id="B3" value="61.5" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="287"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="436"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="234"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Subjective Total Sleep Time (sTSTm)</title>
          <description>The baseline sTSTm was defined as the participant’s reported total amount of time spent asleep before waking for the day (measured in minutes), calculated as the mean of the last 7 (non-missing) daily e-diary values obtained during the placebo run-in phase.
(n=517, n=254)</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="320.4" spread="76.1"/>
                    <measurement group_id="B2" value="329.9" spread="79.4"/>
                    <measurement group_id="B3" value="323.5" spread="77.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Subjective Time to Sleep Onset in minutes (sTSOm)</title>
          <description>The baseline sTSOm was defined as the participant’s reported time that he or she required to fall asleep (measured in minutes), calculated as the mean of the last 7 (non-missing) daily e-diary values obtained during the placebo run-in phase.
(n=517, n=254)</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.9" spread="63.8"/>
                    <measurement group_id="B2" value="65.0" spread="60.6"/>
                    <measurement group_id="B3" value="65.6" spread="62.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced Cataplexy Adverse Events (AEs) During the Double-Blind (DB) Treatment Phase</title>
        <description>Cataplexy is defined as a sudden loss of muscle tone while awake which prevents voluntary movement.</description>
        <time_frame>From the first day of study treatment up to 12 months</time_frame>
        <population>All Participants as Treated (APaT) population; all randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant</title>
            <description>After a 1-week single-blind placebo run-in, participants received suvorexant (40 mg for participants aged 18 to &lt;65 years; and 30 mg for participants aged ≥65 years) daily before bedtime for 12 months during the double-blind (DB) Treatment Phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>After a 1-week single-blind placebo run-in, participants received dose-matched placebo to suvorexant (administered according to age) daily before bedtime for 12 months during the DB Treatment Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Cataplexy Adverse Events (AEs) During the Double-Blind (DB) Treatment Phase</title>
          <description>Cataplexy is defined as a sudden loss of muscle tone while awake which prevents voluntary movement.</description>
          <population>All Participants as Treated (APaT) population; all randomized participants who received at least one dose of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="521"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced Sleep Paralysis AEs During the DB Treatment Phase</title>
        <description>Sleep paralysis was defined as the inability to perform voluntary muscle movements during sleep. Sleep paralysis adverse events included sleep-onset paralysis (paralysis as one is falling asleep).</description>
        <time_frame>From the first day of study treatment up to 12 months</time_frame>
        <population>All Participants as Treated (APaT) population; all randomized participants who received at least one dose of study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant</title>
            <description>After a 1-week single-blind placebo run-in, participants received suvorexant (40 mg for participants aged 18 to &lt;65 years; and 30 mg for participants aged ≥65 years) daily before bedtime for 12 months during the double-blind (DB) Treatment Phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>After a 1-week single-blind placebo run-in, participants received dose-matched placebo to suvorexant (administered according to age) daily before bedtime for 12 months during the DB Treatment Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Sleep Paralysis AEs During the DB Treatment Phase</title>
          <description>Sleep paralysis was defined as the inability to perform voluntary muscle movements during sleep. Sleep paralysis adverse events included sleep-onset paralysis (paralysis as one is falling asleep).</description>
          <population>All Participants as Treated (APaT) population; all randomized participants who received at least one dose of study treatment</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="521"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The method of Miettinen and Nurminen was used to construct the confidence interval for the difference in the percentage of participants with any sleep paralysis AEs between the Suvorexant group and Placebo group .</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced Complex Sleep-related Behaviors AEs During the DB Treatment Phase</title>
        <description>Complex sleep-related behaviors were reported as ECIs and were characterized by patients engaging in specific activities while asleep (e.g., eating, drinking, preparing meals, making phone calls, having sex, driving, and sleep walking).</description>
        <time_frame>From the first day of study treatment up to 12 months</time_frame>
        <population>All Participants as Treated (APaT) population; all randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant</title>
            <description>After a 1-week single-blind placebo run-in, participants received suvorexant (40 mg for participants aged 18 to &lt;65 years; and 30 mg for participants aged ≥65 years) daily before bedtime for 12 months during the double-blind (DB) Treatment Phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>After a 1-week single-blind placebo run-in, participants received dose-matched placebo to suvorexant (administered according to age) daily before bedtime for 12 months during the DB Treatment Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Complex Sleep-related Behaviors AEs During the DB Treatment Phase</title>
          <description>Complex sleep-related behaviors were reported as ECIs and were characterized by patients engaging in specific activities while asleep (e.g., eating, drinking, preparing meals, making phone calls, having sex, driving, and sleep walking).</description>
          <population>All Participants as Treated (APaT) population; all randomized participants who received at least one dose of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="521"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>any complex sleep-related behaviors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>somnambulism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The method of Miettinen and Nurminen was used to construct the confidence interval for the difference in the percentage of participants with any complex sleep-related behaviors AEs between the Suvorexant group and Placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.482</p_value>
            <method>Miettinen &amp; Nurminen Method.</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced Falls AEs During the DB Treatment Phase</title>
        <description>Falls were adjudicated (to establish whether a fall event was due to cataplexy).</description>
        <time_frame>From the first day of study treatment up to 12 months</time_frame>
        <population>All Participants as Treated (APaT) population; all randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant</title>
            <description>After a 1-week single-blind placebo run-in, participants received suvorexant (40 mg for participants aged 18 to &lt;65 years; and 30 mg for participants aged ≥65 years) daily before bedtime for 12 months during the double-blind (DB) Treatment Phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>After a 1-week single-blind placebo run-in, participants received dose-matched placebo to suvorexant (administered according to age) daily before bedtime for 12 months during the DB Treatment Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Falls AEs During the DB Treatment Phase</title>
          <description>Falls were adjudicated (to establish whether a fall event was due to cataplexy).</description>
          <population>All Participants as Treated (APaT) population; all randomized participants who received at least one dose of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="521"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The method of Miettinen and Nurminen was used to calculate the p-value and construct the confidence interval for the difference in the percentage of participants with any falls AEs between the Suvorexant group and Placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.508</p_value>
            <method>Miettinen &amp; Nurminen Method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced Suicidal Ideation and/or Behavior AEs During the DB Treatment Phase</title>
        <description>Suicidal ideation included suicidal plans, suicidal tendency, death wishes, life weariness, and suicidal intention. Suicidal behaviors included suicide attempts, suicide gesture, and self-injurious behaviour. Suicidal ideation and/or behavior was reported as an AE and considered an ECI.</description>
        <time_frame>From the first day of study treatment up to 12 months</time_frame>
        <population>All Participants as Treated (APaT) population; all randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant</title>
            <description>After a 1-week single-blind placebo run-in, participants received suvorexant (40 mg for participants aged 18 to &lt;65 years; and 30 mg for participants aged ≥65 years) daily before bedtime for 12 months during the double-blind (DB) Treatment Phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>After a 1-week single-blind placebo run-in, participants received dose-matched placebo to suvorexant (administered according to age) daily before bedtime for 12 months during the DB Treatment Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Suicidal Ideation and/or Behavior AEs During the DB Treatment Phase</title>
          <description>Suicidal ideation included suicidal plans, suicidal tendency, death wishes, life weariness, and suicidal intention. Suicidal behaviors included suicide attempts, suicide gesture, and self-injurious behaviour. Suicidal ideation and/or behavior was reported as an AE and considered an ECI.</description>
          <population>All Participants as Treated (APaT) population; all randomized participants who received at least one dose of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="521"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The method of Miettinen and Nurminen was used to calculate the p-value and construct the confidence interval for the difference in the percentage of participants with any suicidal ideation/behavior AEs considered an ECI between the Suvorexant group and Placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.159</p_value>
            <method>Miettinen &amp; Nurminen Method</method>
            <param_type>Difference in Percentage of AEs</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced Hypnagogic/Hypnopompic Hallucinations AEs During the DB Treatment Phase</title>
        <description>Perceptual distortions associated with transitions between wakefulness and sleep were termed as hypnagogic (occurring during the onset of sleep) or hypnopompic (occurring during onset of wakefulness) hallucinations.</description>
        <time_frame>From the first day of study treatment up to 12 months</time_frame>
        <population>All Participants as Treated (APaT) population; all randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant</title>
            <description>After a 1-week single-blind placebo run-in, participants received suvorexant (40 mg for participants aged 18 to &lt;65 years; and 30 mg for participants aged ≥65 years) daily before bedtime for 12 months during the double-blind (DB) Treatment Phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>After a 1-week single-blind placebo run-in, participants received dose-matched placebo to suvorexant (administered according to age) daily before bedtime for 12 months during the DB Treatment Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Hypnagogic/Hypnopompic Hallucinations AEs During the DB Treatment Phase</title>
          <description>Perceptual distortions associated with transitions between wakefulness and sleep were termed as hypnagogic (occurring during the onset of sleep) or hypnopompic (occurring during onset of wakefulness) hallucinations.</description>
          <population>All Participants as Treated (APaT) population; all randomized participants who received at least one dose of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="521"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any hypnagogic/hypnopompic hallucinations AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypnagogic hallucination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypnopompic hallucination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The method of Miettinen and Nurminen was used to calculate the p-value and construct the confidence interval for the difference in the percentage of participants with any Hypnagogic/hypnopompic hallucinations AEs between the Suvorexant group and Placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.159</p_value>
            <method>Miettinen &amp; Nurminen Method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced Selected AEs Associated With Potential for Abuse During the DB Treatment Phase</title>
        <description>The pre-specified terms which were suggestive of abuse potential on this study included depersonalization (feeling of watching oneself act, while having no control over a situation), derealization (alteration in the perception or experience of the external world so that it seems unreal), dissociation (includes a wide array of experiences from mild detachment from immediate surroundings to more severe detachment from physical and emotional experience), euphoric mood (exaggerated feeling of physical and emotional well-being and optimism not consonant with apparent stimuli or events), mania (state of abnormally elevated or irritable mood, arousal, and/or energy levels), hallucination (perception in the absence of a stimulus which has qualities of real perception), and potential study medication misuse.</description>
        <time_frame>From the first day of study treatment up to 12 months</time_frame>
        <population>All Participants as Treated (APaT) population; all randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant</title>
            <description>After a 1-week single-blind placebo run-in, participants received suvorexant (40 mg for participants aged 18 to &lt;65 years; and 30 mg for participants aged ≥65 years) daily before bedtime for 12 months during the double-blind (DB) Treatment Phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>After a 1-week single-blind placebo run-in, participants received dose-matched placebo to suvorexant (administered according to age) daily before bedtime for 12 months during the DB Treatment Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Selected AEs Associated With Potential for Abuse During the DB Treatment Phase</title>
          <description>The pre-specified terms which were suggestive of abuse potential on this study included depersonalization (feeling of watching oneself act, while having no control over a situation), derealization (alteration in the perception or experience of the external world so that it seems unreal), dissociation (includes a wide array of experiences from mild detachment from immediate surroundings to more severe detachment from physical and emotional experience), euphoric mood (exaggerated feeling of physical and emotional well-being and optimism not consonant with apparent stimuli or events), mania (state of abnormally elevated or irritable mood, arousal, and/or energy levels), hallucination (perception in the absence of a stimulus which has qualities of real perception), and potential study medication misuse.</description>
          <population>All Participants as Treated (APaT) population; all randomized participants who received at least one dose of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="521"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>any selected AE of potential abuse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug maladministration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Derealisation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hallucination, auditory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hallucination, visual</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypnagogic hallucination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypnopompic hallucination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The method of Miettinen and Nurminen was used to calculate the p-value and construct the confidence interval for the difference in the percentage of participants with any selected AEs associated with potential abuse between the Suvorexant group and Placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.767</p_value>
            <method>Miettinen &amp; Nurminen Method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.8</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Withdrawal Symptoms During the DB Run-Out Phase: Tyrer Withdrawal Symptom Questionnaire (WSQ)</title>
        <description>Withdrawal effects assessed using Tyrer WSQ, which evaluated the presence/absence and severity of withdrawal symptoms with 20 items (i.e. sensitivity to noise, light, smell, touch, feeling unreal, etc). The Tyrer WSQ was completed as part of the evening e-diary prior to dosing on the Month 12 visit and on the 3 consecutive evenings of the DB Run-out Phase (first 3 nights of DB Discontinuation Phase). Responses rated 0 (No), 1 (Yes-moderate), or 2 (Yes-severe); range from 0 (no withdrawal) to 40 (severe withdrawal).
A participant was defined to have a withdrawal symptom if an item during any of the 3 DB Run-out days had emerged for the first time, or had worsened compared to the measurement obtained at the end of the Treatment phase (Month 12). For single night analysis, a patient was defined to have withdrawal effects if the number of withdrawal symptoms (emergent or worsening) was ≥3. For across night analysis, withdrawal was defined as a total of ≥3 symptoms across the 3 nights.</description>
        <time_frame>Evening of Month 12 visit and next 3 consecutive days (Night 1, 2, and 3 of Discontinuation Phase [otherwise known as the Run-out])</time_frame>
        <population>Participants in the APaT population who completed the entire DB Treatment Phase, had at least one measurement at the end of the DB Treatment Phase (Month 12), had taken at least one dose of Run-out study medication, and had a measurement on at least one of the nights of the DB Run-out Phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant (DB Treatment)/Suvorexant (DB Discontinuation)</title>
            <description>Following treatment with suvorexant during the 12-Month DB Treatment Period, participants received their same dose of suvorexant during a 2-month DB Discontinuation Period.</description>
          </group>
          <group group_id="O2">
            <title>Suvorexant (DB Treatment)/Placebo (DB Discontinuation)</title>
            <description>Following treatment with suvorexant during the 12-Month DB Treatment Period, participants received dose-matched placebo to suvorexant during a 2-month DB Discontinuation Period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (DB Treatment)/Placebo (DB Discontinuation)</title>
            <description>Following treatment with dose-matched placebo to suvorexant during the 12-Month DB Treatment Period, participants continued to receive dose-matched placebo to suvorexant during a 2-month DB Discontinuation Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Withdrawal Symptoms During the DB Run-Out Phase: Tyrer Withdrawal Symptom Questionnaire (WSQ)</title>
          <description>Withdrawal effects assessed using Tyrer WSQ, which evaluated the presence/absence and severity of withdrawal symptoms with 20 items (i.e. sensitivity to noise, light, smell, touch, feeling unreal, etc). The Tyrer WSQ was completed as part of the evening e-diary prior to dosing on the Month 12 visit and on the 3 consecutive evenings of the DB Run-out Phase (first 3 nights of DB Discontinuation Phase). Responses rated 0 (No), 1 (Yes-moderate), or 2 (Yes-severe); range from 0 (no withdrawal) to 40 (severe withdrawal).
A participant was defined to have a withdrawal symptom if an item during any of the 3 DB Run-out days had emerged for the first time, or had worsened compared to the measurement obtained at the end of the Treatment phase (Month 12). For single night analysis, a patient was defined to have withdrawal effects if the number of withdrawal symptoms (emergent or worsening) was ≥3. For across night analysis, withdrawal was defined as a total of ≥3 symptoms across the 3 nights.</description>
          <population>Participants in the APaT population who completed the entire DB Treatment Phase, had at least one measurement at the end of the DB Treatment Phase (Month 12), had taken at least one dose of Run-out study medication, and had a measurement on at least one of the nights of the DB Run-out Phase.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Withdrawal Symptoms on Night 1 (n=121, 122, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="1.6"/>
                    <measurement group_id="O3" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawal Symptoms on Night 2 (n=121, 124, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="3.2"/>
                    <measurement group_id="O3" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawal Symptoms on Night 3 (n=116, 120, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="2.5"/>
                    <measurement group_id="O3" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptoms Across Nights 1, 2, &amp; 3 (n=129, 129, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2"/>
                    <measurement group_id="O2" value="6.2"/>
                    <measurement group_id="O3" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The method of Miettinen and Nurminen was used to calculate the p-value and compute the confidence interval for the point difference in a pairwise comparison of the percentage of participants with withdrawal symptoms during Night 1 in the Suvorexant (DB Treatment)/Suvorexant (DB Discontinuation) group vs. the Suvorexant (DB Treatment)/Placebo (DB Discontinuation) group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.567</p_value>
            <method>Miettinen &amp; Nurminen Method</method>
            <param_type>Difference in Percentage: Night 1</param_type>
            <param_value>-0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.1</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The method of Miettinen and Nurminen was used to calculate the p-value and compute the confidence interval for the point difference in a pairwise comparison of the percentage of participants with withdrawal symptoms during Night 2 in the Suvorexant (DB Treatment)/Suvorexant (DB Discontinuation) group vs. the Suvorexant (DB Treatment)/Placebo (DB Discontinuation) group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.185</p_value>
            <method>Miettinen &amp; Nurminen Method</method>
            <param_type>Difference in Percentage: Night 2</param_type>
            <param_value>-2.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The method of Miettinen and Nurminen was used to calculate the p-value and compute the confidence interval for the point difference in a pairwise comparison of the percentage of participants with withdrawal symptoms during Night 3 in the Suvorexant (DB Treatment)/Suvorexant (DB Discontinuation) group vs. the Suvorexant (DB Treatment)/Placebo (DB Discontinuation) group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.680</p_value>
            <method>Miettinen &amp; Nurminen Method</method>
            <param_type>Difference in Percentage: Night 3</param_type>
            <param_value>-0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.6</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The method of Miettinen and Nurminen was used to calculate the p-value and compute the confidence interval for the point difference in a pairwise comparison of the percentage of participants with withdrawal symptoms across Nights 1, 2, and 3 in the Suvorexant (DB Treatment)/Suvorexant (DB Discontinuation) group vs. the Suvorexant (DB Treatment)/Placebo (DB Discontinuation) group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Miettinen &amp; Nurminen Method</method>
            <param_type>Difference in Percentage: Across Nights</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.4</ci_lower_limit>
            <ci_upper_limit>6.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Rebound As Defined By Decreased Subjective Total Sleep Time (sTST) During the DB Run-Out Phase</title>
        <description>Rebound insomnia was defined as insomnia that occurred following discontinuation of a sedative substance taken to relieve primary insomnia, and was assessed based on subjective total sleep time (sTST) as recorded in the participant’s morning e-diary. A strict categorical analysis method (Yes/No) was used in which a participant was considered to have potentially experienced rebound (Yes) if the Morning Diary participant-reported sTST value (in minutes) on any of the 3 nights of the Run-out Phase (first 3 nights of the Discontinuation Phase) occurring after one year of treatment (Month 13) was less than the last value at baseline one year earlier (Month 1).</description>
        <time_frame>Baseline (Month 1) and first 3 days of Randomized Discontinuation Phase (otherwise known as the Run-out, Month 13)</time_frame>
        <population>Participants in the APaT population who completed the entire DB Treatment Phase, had a baseline measurement, had taken at least one dose of DB Run-out study medication, and had a measurement on at least one of the nights of the DB Run-out Phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant (DB Treatment)/Suvorexant (DB Discontinuation)</title>
            <description>Following treatment with suvorexant during the 12-Month DB Treatment Period, participants received their same dose of suvorexant during a 2-month DB Discontinuation Period.</description>
          </group>
          <group group_id="O2">
            <title>Suvorexant (DB Treatment)/Placebo (DB Discontinuation)</title>
            <description>Following treatment with suvorexant during the 12-Month DB Treatment Period, participants received dose-matched placebo to suvorexant during a 2-month DB Discontinuation Period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (DB Treatment)/Placebo (DB Discontinuation)</title>
            <description>Following treatment with dose-matched placebo to suvorexant during the 12-Month DB Treatment Period, participants continued to receive dose-matched placebo to suvorexant during a 2-month DB Discontinuation Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Rebound As Defined By Decreased Subjective Total Sleep Time (sTST) During the DB Run-Out Phase</title>
          <description>Rebound insomnia was defined as insomnia that occurred following discontinuation of a sedative substance taken to relieve primary insomnia, and was assessed based on subjective total sleep time (sTST) as recorded in the participant’s morning e-diary. A strict categorical analysis method (Yes/No) was used in which a participant was considered to have potentially experienced rebound (Yes) if the Morning Diary participant-reported sTST value (in minutes) on any of the 3 nights of the Run-out Phase (first 3 nights of the Discontinuation Phase) occurring after one year of treatment (Month 13) was less than the last value at baseline one year earlier (Month 1).</description>
          <population>Participants in the APaT population who completed the entire DB Treatment Phase, had a baseline measurement, had taken at least one dose of DB Run-out study medication, and had a measurement on at least one of the nights of the DB Run-out Phase.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rebound on Night 1 (n=137, 142, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5"/>
                    <measurement group_id="O2" value="33.8"/>
                    <measurement group_id="O3" value="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rebound on Night 2 (n=138, 146, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6"/>
                    <measurement group_id="O2" value="35.6"/>
                    <measurement group_id="O3" value="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rebound on Night 3 (n=131, 146, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8"/>
                    <measurement group_id="O2" value="37.7"/>
                    <measurement group_id="O3" value="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rebound on Nights 1, 2 or 3 (n=152, 157, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9"/>
                    <measurement group_id="O2" value="51.0"/>
                    <measurement group_id="O3" value="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The method of Miettinen and Nurminen was used to calculate the p-value and compute the confidence interval for the point difference in a pairwise comparison of the percentage of participants with sTST rebound effects during Night 1 in the Suvorexant (DB Treatment)/Suvorexant (DB Discontinuation) group vs. the Placebo (DB Treatment)/Placebo (DB Discontinuation) group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.365</p_value>
            <method>Miettinen &amp; Nurminen Method</method>
            <param_type>Difference in Percentage: Night 1</param_type>
            <param_value>5.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.8</ci_lower_limit>
            <ci_upper_limit>15.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The method of Miettinen and Nurminen was used to calculate the p-value and compute the confidence interval for the point difference in a pairwise comparison of the percentage of participants with sTST rebound effects during Night 2 in the Suvorexant (DB Treatment)/Suvorexant (DB Discontinuation) group vs. the Placebo (DB Treatment)/Placebo (DB Discontinuation) group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.109</p_value>
            <method>Miettinen &amp; Nurminen Method</method>
            <param_type>Difference in Percentage: Night 2</param_type>
            <param_value>8.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>19.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The method of Miettinen and Nurminen was used to calculate the p-value and compute the confidence interval for the point difference in a pairwise comparison of the percentage of participants with sTST rebound effects during Night 3 in the Suvorexant (DB Treatment)/Suvorexant (DB Discontinuation) group vs. the Placebo (DB Treatment)/Placebo (DB Discontinuation) group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.287</p_value>
            <method>Miettinen &amp; Nurminen Method</method>
            <param_type>Difference in Percentage: Night 3</param_type>
            <param_value>6.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.1</ci_lower_limit>
            <ci_upper_limit>16.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The method of Miettinen and Nurminen was used to calculate the p-value and compute the confidence interval for the point difference in a pairwise comparison of the percentage of participants with sTST rebound effects during Nights 1, 2, or 3 in the Suvorexant (DB Treatment)/Suvorexant (DB Discontinuation) group vs. the Placebo (DB Treatment)/Placebo (DB Discontinuation) group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.057</p_value>
            <method>Miettinen &amp; Nurminen Method</method>
            <param_type>Difference in Percentage:Night 1, 2 or 3</param_type>
            <param_value>10.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>21.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Rebound As Defined By Increased Subjective Time to Sleep Onset (sTSO) During the DB Run-Out Phase</title>
        <description>Rebound insomnia was defined as insomnia that occurred following discontinuation of a sedative substance taken to relieve primary insomnia, and was assessed based on subjective time to sleep onset (sTSO) as recorded in the participant’s morning e-diary. A strict categorical analysis method (Yes/No) was used in which a participant was considered to have potentially experienced rebound (Yes) if the Morning Diary participant-reported sTSO value (in minutes) on any of the first 3 nights of the Run-out Phase occurring after one year of treatment (Month 13) was greater than the last value at baseline one year earlier (Month 1).</description>
        <time_frame>Baseline (Month 1) and first 3 days of Randomized Discontinuation Phase (otherwise known as the Run-out, Month 13)</time_frame>
        <population>Participants in the APaT population who completed the entire DB Treatment Phase, had a baseline measurement, had taken at least one dose of DB Run-out study medication, and had a measurement on at least one of the nights of the DB Run-out Phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant (DB Treatment)/Suvorexant (DB Discontinuation)</title>
            <description>Following treatment with suvorexant during the 12-Month DB Treatment Period, participants received their same dose of suvorexant during a 2-month DB Discontinuation Period.</description>
          </group>
          <group group_id="O2">
            <title>Suvorexant (DB Treatment)/Placebo (DB Discontinuation)</title>
            <description>Following treatment with suvorexant during the 12-Month DB Treatment Period, participants received dose-matched placebo to suvorexant during a 2-month DB Discontinuation Period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (DB Treatment)/Placebo (DB Discontinuation)</title>
            <description>Following treatment with dose-matched placebo to suvorexant during the 12-Month DB Treatment Period, participants continued to receive dose-matched placebo to suvorexant during a 2-month DB Discontinuation Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Rebound As Defined By Increased Subjective Time to Sleep Onset (sTSO) During the DB Run-Out Phase</title>
          <description>Rebound insomnia was defined as insomnia that occurred following discontinuation of a sedative substance taken to relieve primary insomnia, and was assessed based on subjective time to sleep onset (sTSO) as recorded in the participant’s morning e-diary. A strict categorical analysis method (Yes/No) was used in which a participant was considered to have potentially experienced rebound (Yes) if the Morning Diary participant-reported sTSO value (in minutes) on any of the first 3 nights of the Run-out Phase occurring after one year of treatment (Month 13) was greater than the last value at baseline one year earlier (Month 1).</description>
          <population>Participants in the APaT population who completed the entire DB Treatment Phase, had a baseline measurement, had taken at least one dose of DB Run-out study medication, and had a measurement on at least one of the nights of the DB Run-out Phase.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rebound on Night 1 (n=137, 142, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8"/>
                    <measurement group_id="O2" value="26.8"/>
                    <measurement group_id="O3" value="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rebound on Night 2 (n=138, 146, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="30.1"/>
                    <measurement group_id="O3" value="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rebound on Night 3 (n=131, 146, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1"/>
                    <measurement group_id="O2" value="30.1"/>
                    <measurement group_id="O3" value="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rebound on Nights 1, 2 or 3 (n=152, 157, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6"/>
                    <measurement group_id="O2" value="40.8"/>
                    <measurement group_id="O3" value="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The method of Miettinen and Nurminen was used to calculate the p-value and compute the confidence interval for the point difference in a pairwise comparison of the percentage of participants with sTSO rebound effects during Night 1 in the Suvorexant (DB Treatment)/Suvorexant (DB Discontinuation) group vs. the Placebo (DB Treatment)/Placebo (DB Discontinuation) group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.386</p_value>
            <method>Miettinen &amp; Nurminen Method</method>
            <param_type>Difference in Percentage: Night 1</param_type>
            <param_value>4.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.7</ci_lower_limit>
            <ci_upper_limit>14.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The method of Miettinen and Nurminen was used to calculate the p-value and compute the confidence interval for the point difference in a pairwise comparison of the percentage of participants with sTSO rebound effects during Night 2 in the Suvorexant (DB Treatment)/Suvorexant (DB Discontinuation) group vs. the Placebo (DB Treatment)/Placebo (DB Discontinuation) group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.311</p_value>
            <method>Miettinen &amp; Nurminen Method</method>
            <param_type>Difference in Percentage: Night 2</param_type>
            <param_value>5.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>15.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The method of Miettinen and Nurminen was used to calculate the p-value and compute the confidence interval for the point difference in a pairwise comparison of the percentage of participants with sTSO rebound effects during Night 3 in the Suvorexant (DB Treatment)/Suvorexant (DB Discontinuation) group vs. the Placebo (DB Treatment)/Placebo (DB Discontinuation) group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.351</p_value>
            <method>Miettinen &amp; Nurminen Method</method>
            <param_type>Difference in Percentage: Night 3</param_type>
            <param_value>4.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.5</ci_lower_limit>
            <ci_upper_limit>15.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The method of Miettinen and Nurminen was used to calculate the p-value and compute the confidence interval for the point difference in a pairwise comparison of the percentage of participants with sTSO rebound effects during Nights 1, 2, or 3 in the Suvorexant (DB Treatment)/Suvorexant (DB Discontinuation) group vs. the Placebo (DB Treatment)/Placebo (DB Discontinuation) group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.409</p_value>
            <method>Miettinen &amp; Nurminen Method</method>
            <param_type>Difference in Percentage:Night 1, 2 or 3</param_type>
            <param_value>4.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.3</ci_lower_limit>
            <ci_upper_limit>15.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Least Squares (LS) Mean Change From Baseline in Mean Subjective Total Sleep Time (sTSTm) During First Month of Treatment Phase</title>
        <description>The sTSTm was defined as the average over time of daily e-diary values for a participant's report of the total amount of time spent asleep before waking for the day (measured in minutes). Weekly sTSTm values (Week 1, Week 2, etc.) were the average of the daily e-diary values for the week. A summary value of this measure for Month 1 was obtained by taking the average of weekly sTSTm values for Weeks 1 through 4; (Week 1 + Week 2 + Week 3 + Week 4) ÷ 4. LS Mean Change from Baseline in sTSTm was then calculated at Week 1, Week 2, Week 3, Week 4, and Month 1.</description>
        <time_frame>Baseline, Week 1, Week 2, Week 3, and Week 4</time_frame>
        <population>Full Analysis Set (FAS)-Efficacy; all randomized participants who had ≥1 post-randomization observation for the analysis endpoint subsequent to ≥1 dose of study treatment, and baseline data for those analyses that required baseline data. The number included in the FAS may vary across endpoints due to the degree of missing data for each endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant</title>
            <description>After a 1-week single-blind placebo run-in, participants received suvorexant (40 mg for participants aged 18 to &lt;65 years; and 30 mg for participants aged ≥65 years) daily before bedtime for 12 months during the double-blind (DB) Treatment Phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>After a 1-week single-blind placebo run-in, participants received dose-matched placebo to suvorexant (administered according to age) daily before bedtime for 12 months during the DB Treatment Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares (LS) Mean Change From Baseline in Mean Subjective Total Sleep Time (sTSTm) During First Month of Treatment Phase</title>
          <description>The sTSTm was defined as the average over time of daily e-diary values for a participant's report of the total amount of time spent asleep before waking for the day (measured in minutes). Weekly sTSTm values (Week 1, Week 2, etc.) were the average of the daily e-diary values for the week. A summary value of this measure for Month 1 was obtained by taking the average of weekly sTSTm values for Weeks 1 through 4; (Week 1 + Week 2 + Week 3 + Week 4) ÷ 4. LS Mean Change from Baseline in sTSTm was then calculated at Week 1, Week 2, Week 3, Week 4, and Month 1.</description>
          <population>Full Analysis Set (FAS)-Efficacy; all randomized participants who had ≥1 post-randomization observation for the analysis endpoint subsequent to ≥1 dose of study treatment, and baseline data for those analyses that required baseline data. The number included in the FAS may vary across endpoints due to the degree of missing data for each endpoint.</population>
          <units>minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="517"/>
                <count group_id="O2" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change From BL at Week 1 (N=508, 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1" lower_limit="36.9" upper_limit="45.3"/>
                    <measurement group_id="O2" value="14.1" lower_limit="8.2" upper_limit="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From BL at Week 2 (N=495, 248)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" lower_limit="28.1" upper_limit="36.7"/>
                    <measurement group_id="O2" value="14.7" lower_limit="8.6" upper_limit="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From BL at Week 3 (N=488, 241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6" lower_limit="35.3" upper_limit="44.0"/>
                    <measurement group_id="O2" value="16.4" lower_limit="10.3" upper_limit="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From BL at Week 4 (N=473, 238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.6" lower_limit="37.1" upper_limit="46.1"/>
                    <measurement group_id="O2" value="18.7" lower_limit="12.3" upper_limit="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From BL at Month 1 Average (N=517, 254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7" lower_limit="35.0" upper_limit="42.3"/>
                    <measurement group_id="O2" value="16.0" lower_limit="10.8" upper_limit="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A Longitudinal Data Analysis Model was used to test the difference in LS mean change from baseline in sTSTm for Month 1 (Average of Weeks 1, 2, 3, 4) in the Suvorexant group vs. the Placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>To account for multiplicity, Hochberg’s procedure was used to control the overall Type I error rate at the 5% level.</p_value_desc>
            <method>Longitudinal Data Analysis</method>
            <param_type>Difference in LS Means: Month 1</param_type>
            <param_value>22.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.4</ci_lower_limit>
            <ci_upper_limit>29.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Least Squares (LS) Mean Change From Baseline in Mean Subjective Time To Sleep Onset (sTSOm) During First Month of Treatment Phase</title>
        <description>The sTSOm was defined as the average over time of daily e-diary values for a participant's report of the time he or she required to fall asleep (measured in minutes). Weekly sTSOm values (Week 1, Week 2, etc.) were the average of the daily e-diary values for the week. A summary value of this measure for Month 1 was obtained by taking the average of weekly sTSTm values for Weeks 1 through 4; (Week 1 + Week 2 + Week 3 + Week 4) ÷ 4. LS Mean Change from Baseline in sTSOm was then calculated at Week 1, Week 2, Week 3, Week 4, and Month 1.</description>
        <time_frame>Baseline, Week 1, Week 2, Week 3, and Week 4</time_frame>
        <population>Full Analysis Set (FAS)-Efficacy; all randomized participants who had ≥1 post-randomization observation for the analysis endpoint subsequent to ≥1 dose of study treatment, and baseline data for those analyses that required baseline data. The number included in the FAS may vary across endpoints due to the degree of missing data for each endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant</title>
            <description>After a 1-week single-blind placebo run-in, participants received suvorexant (40 mg for participants aged 18 to &lt;65 years; and 30 mg for participants aged ≥65 years) daily before bedtime for 12 months during the double-blind (DB) Treatment Phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>After a 1-week single-blind placebo run-in, participants received dose-matched placebo to suvorexant (administered according to age) daily before bedtime for 12 months during the DB Treatment Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares (LS) Mean Change From Baseline in Mean Subjective Time To Sleep Onset (sTSOm) During First Month of Treatment Phase</title>
          <description>The sTSOm was defined as the average over time of daily e-diary values for a participant's report of the time he or she required to fall asleep (measured in minutes). Weekly sTSOm values (Week 1, Week 2, etc.) were the average of the daily e-diary values for the week. A summary value of this measure for Month 1 was obtained by taking the average of weekly sTSTm values for Weeks 1 through 4; (Week 1 + Week 2 + Week 3 + Week 4) ÷ 4. LS Mean Change from Baseline in sTSOm was then calculated at Week 1, Week 2, Week 3, Week 4, and Month 1.</description>
          <population>Full Analysis Set (FAS)-Efficacy; all randomized participants who had ≥1 post-randomization observation for the analysis endpoint subsequent to ≥1 dose of study treatment, and baseline data for those analyses that required baseline data. The number included in the FAS may vary across endpoints due to the degree of missing data for each endpoint.</population>
          <units>minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="517"/>
                <count group_id="O2" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change From BL at Week 1 (N=508, 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.7" lower_limit="-20.9" upper_limit="-14.5"/>
                    <measurement group_id="O2" value="-6.8" lower_limit="-11.4" upper_limit="-2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From BL at Week 2 (N=495, 248)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.7" lower_limit="-19.2" upper_limit="-12.2"/>
                    <measurement group_id="O2" value="-7.5" lower_limit="-12.4" upper_limit="-2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From BL at Week 3 (N=488, 241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.7" lower_limit="-22.2" upper_limit="-15.2"/>
                    <measurement group_id="O2" value="-10.0" lower_limit="-14.9" upper_limit="-5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From BL at Week 4 (N=473, 238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.9" lower_limit="-23.1" upper_limit="-16.6"/>
                    <measurement group_id="O2" value="-9.4" lower_limit="-14.1" upper_limit="-4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From BL at Month 1 Average (N=517, 254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.0" lower_limit="-20.9" upper_limit="-15.1"/>
                    <measurement group_id="O2" value="-8.4" lower_limit="-12.5" upper_limit="-4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A Longitudinal Data Analysis Model was used to test the difference in LS mean change from baseline in sTSOm for Month 1 (Average of Weeks 1, 2, 3, 4) in the Suvorexant group vs. the Placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>To account for multiplicity, Hochberg’s procedure was used to control the overall Type I error rate at the 5% level.</p_value_desc>
            <method>Longitudinal Data Analysis</method>
            <param_type>Difference in LS Means: Month 1</param_type>
            <param_value>-9.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.6</ci_lower_limit>
            <ci_upper_limit>-4.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Who Reported Suicidal Ideation and/or Behavior On Study Based on Responses to the Columbia Suicide Severity Rating Scale (C-SSRS)</title>
        <description>Suicidal ideation and/or behavior that occurred on study was also assessed using the C-SSRS, a rater-administered questionnaire used to prospectively assess suicidal ideation and suicidal behavior. C-SSRS assessment was based upon a clinician's interpretation of the participant's responses to the C-SSRS questions, not by a numbered scale.
Suicidal ideation and/or behaviors identified on the C-SSRS may not have been considered an adverse event, based on the investigator's judgment.</description>
        <time_frame>From the first day of study treatment through study follow-up (up to 14 months)</time_frame>
        <population>All Participants as Treated (APaT) population; all randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant</title>
            <description>After a 1-week single-blind placebo run-in, participants received suvorexant (40 mg for participants aged 18 to &lt;65 years; and 30 mg for participants aged ≥65 years) daily before bedtime for 12 months during the double-blind (DB) Treatment Phase. Following the Treatment Phase, these participants were randomized (at baseline) to suvorexant or placebo during the 2-month Randomized Discontinuation Phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>After a 1-week single-blind placebo run-in, participants received dose-matched placebo to suvorexant (administered according to age) daily before bedtime for 12 months during the DB Treatment Phase. Following the Treatment Phase, these participants continued on placebo during the 2-month Randomized Discontinuation Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Reported Suicidal Ideation and/or Behavior On Study Based on Responses to the Columbia Suicide Severity Rating Scale (C-SSRS)</title>
          <description>Suicidal ideation and/or behavior that occurred on study was also assessed using the C-SSRS, a rater-administered questionnaire used to prospectively assess suicidal ideation and suicidal behavior. C-SSRS assessment was based upon a clinician's interpretation of the participant's responses to the C-SSRS questions, not by a numbered scale.
Suicidal ideation and/or behaviors identified on the C-SSRS may not have been considered an adverse event, based on the investigator's judgment.</description>
          <population>All Participants as Treated (APaT) population; all randomized participants who received at least one dose of study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="521"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were monitored from the time of the Prestudy Visit (~Study Day -14) up to the completion of the Follow-up call, occurring 14 days after Randomized Discontinuation Phase (~Study Day 420) or after the last dose of medication, whichever point was later.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Suvorexant</title>
          <description>After a 1-week single-blind placebo run-in, participants received suvorexant (40 mg for participants aged 18 to &lt;65 years; and 30 mg for participants aged ≥65 years) daily before bedtime for 12 months during the double-blind (DB) Treatment Phase.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>After a 1-week single-blind placebo run-in, participants received dose-matched placebo to suvorexant (administered according to age) daily before bedtime for 12 months during the DB Treatment Phase.</description>
        </group>
        <group group_id="E3">
          <title>Suvorexant (DB Treatment)/Suvorexant (DB Discontinuation)</title>
          <description>Following treatment with suvorexant during the 12-Month DB Treatment Phase, participants received their same dose of suvorexant during a 2-month DB Randomized Discontinuation Phase.</description>
        </group>
        <group group_id="E4">
          <title>Suvorexant (DB Treatment)/Placebo (DB Discontinuation)</title>
          <description>Following treatment with suvorexant during the 12-Month DB Treatment Phase, participants received dose-matched placebo to suvorexant during a 2-month DB Randomized Discontinuation Phase.</description>
        </group>
        <group group_id="E5">
          <title>Placebo (DB Treatment)/Placebo (DB Discontinuation)</title>
          <description>Following treatment with dose-matched placebo to suvorexant during the 12-Month DB Treatment Phase, participants continued to receive dose-matched placebo to suvorexant during a 2-month DB Randomized Discontinuation Phase.</description>
        </group>
        <group group_id="E6">
          <title>Suvorexant (DB Treatment)/Suvorexant (DB Run-out)/Follow-up</title>
          <description>Following treatment with suvorexant during both the 12-Month DB Treatment Period and the DB Run-out period, participants entered a Follow-up Phase which concluded with a follow-up phone call 14 days after the last dose of study medication (or 14 days after the Discontinuation visit, whichever time point was later) to report AEs.</description>
        </group>
        <group group_id="E7">
          <title>Suvorexant (DB Treatment)/Placebo (DB Run-out)/Follow-up</title>
          <description>Following treatment with suvorexant during the 12-Month DB Treatment Period and treatment with dose-matched placebo during the DB the Run-out period, participants entered a Follow-up Phase which concluded with a follow-up phone call 14 days after the last dose of study medication (or 14 days after the Discontinuation visit, whichever time point was later) to report AEs.</description>
        </group>
        <group group_id="E8">
          <title>Placebo (DB Treatment)/Placebo (DB Run-out)/Follow-up</title>
          <description>Following treatment with dose-matched placebo during both the 12-Month DB Treatment Period and the DB Run-out period, participants entered a Follow-up Phase which concluded with a follow-up phone call 14 days after the last dose of study medication (or 14 days after the Discontinuation visit, whichever time point was later) to report AEs.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="521"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="258"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrooesophageal reflux</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Meniscal degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="521"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Neoplasm skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="184" subjects_at_risk="521"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="258"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="166"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="40" subjects_affected="34" subjects_at_risk="521"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="53" subjects_affected="42" subjects_at_risk="521"/>
                <counts group_id="E2" events="25" subjects_affected="20" subjects_at_risk="258"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="32" subjects_affected="28" subjects_at_risk="521"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="258"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="29" subjects_affected="24" subjects_at_risk="521"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="66" subjects_affected="43" subjects_at_risk="521"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="258"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="258"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="76" subjects_affected="69" subjects_at_risk="521"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="258"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="258"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Late Stage Development Group Leader</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

